We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

New Technology Quantitatively Analyzes Alzheimer's Biomarkers Using MR and PET Images

By MedImaging International staff writers
Posted on 21 Jul 2023
Print article
Image: Neurophet AQUA is an AI-based degenerative brain disease diagnosis assistant software (Photo courtesy of Neurophet)
Image: Neurophet AQUA is an AI-based degenerative brain disease diagnosis assistant software (Photo courtesy of Neurophet)

A novel treatment for Alzheimer's disease utilizes an anti-amyloid antibody drug to reduce amyloid beta proteins in the brain. However, a common side effect, ARIA (Amyloid-Related Imaging Abnormalities), often appears in brain scans of patients using the drug. Therefore, careful monitoring and management of ARIA is crucial when prescribing anti-amyloid antibody drugs. Now, new cutting-edge brain imaging solutions for Alzheimer's disease treatment can enable the analysis of ARIA, thereby improving efficacy and outcomes.

Neurophet (Seoul, South Korea), an artificial intelligence (AI) solution company specializing in brain diseases, has developed a new technology to examine ARIA-E (edema) typically detected by T2-FLAIR, an MRI sequence, and ARIA-H (hemorrhages), primarily identified by GRE or SWI. An amyloid-PET scan is necessary to observe cortical amyloid beta deposition. Neurophet’s advanced technology predicts amyloid positivity through MR images before conducting amyloid-PET scans. The use of MR images for predicting amyloid positivity could provide a cost-effective solution for clinical trials and prognosis monitoring of Alzheimer's disease treatment, given that amyloid-PET scans are costly and their use and reimbursement are severely restricted. Moreover, PET scans are not universally accessible due to the limited availability of PET scanners.

At the recent Alzheimer's Association International Conference (AAIC) 2023, Neurophet showcased its cutting-edge brain imaging analysis technology, which can be applied in clinical trials and the prescription of new Alzheimer's disease drugs. The company's Neurophet AQUA software, a brain MRI analysis tool, analyzes brain atrophy observed in neurodegenerative diseases like Alzheimer's. Another product, the Neurophet SCALE PET software, quantitatively assesses Alzheimer's disease biomarkers using MR and PET images. It provides quantitative measurement of cortical amyloid beta deposition, a known causative agent of Alzheimer's disease. Neurophet is investing in research and development of analysis technology for ARIA side effects and aims to bring the products to market along with the launch of new Alzheimer's disease treatments.

"Neurophet's major products and technologies are expected to be very useful in the process of clinical trials, diagnosis, side effect monitoring and prognosis observation of Alzheimer's disease treatment." said CEO Jake Junkil Been of Neurophet. "We are going all out to develop solutions related to Alzheimer's disease treatment to preemptively target the high-growth Alzheimer's disease treatment market."

Related Links:

Gold Supplier
IMRT Thorax Phantom
CIRS Model 002LFC
Gold Supplier
Conductive Gel
Radiographic System
RADspeed Pro Style Edition V Series
Lead Apron
Standard Regular Vest

Print article
Sun Nuclear -    Mirion



view channel
Image: The AI model improves tumor removal accuracy during breast cancer surgery (Photo courtesy of UNC School of Medicine)

AI Model Analyzes Tumors Removed Surgically in Real-Time

During breast cancer surgery, the surgeon removes the tumor, also known as a specimen, along with a bit of the adjacent healthy tissue to ensure all cancerous cells are excised. This specimen is then X-rayed... Read more


view channel
Image: FloPatch is a revolutionary tool that facilitates real-time precision in IV fluid management in sepsis (Photo courtesy of Flosonics)

Wireless, Wearable Doppler Ultrasound Revolutionizes Precision Fluid Management in Sepsis Care

When a patient comes to the hospital with sepsis, administering intravenous (IV) fluids is usually the first course of action. However, too much IV fluid can do more harm than good, causing additional... Read more

Nuclear Medicine

view channel
Image: An AI model can evaluate brain tumors on PET (Photo courtesy of Freepik)

AI Model for PET Imaging Determines Patient Response to Brain Tumor Treatments

The assessment of changes in metabolic tumor volume (MTV) through PET scans using specific radiotracers like F-18 fluoroethyl tyrosine (FET) plays a vital role in evaluating the treatment response in patients... Read more

General/Advanced Imaging

view channel
Image: Annalise Enterprise CTB acts like a ‘second pair of eyes’ for radiologists (Photo courtesy of Annalise.ai)

Deep Learning System Boosts Radiologist Accuracy and Speed for Head CTs

Non-contrast computed tomography of the brain (NCCTB) is a commonly employed method for identifying intracranial pathology. Despite its frequent use, the complex scan outcomes are prone to being misunderstood.... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.